Although ADT using several specific AR inhibitors blocks further tumor growth for some patients, most patients develop resistance to the treatment and subsequently develop to castration-resistant PCa (CRPC) associated with poor prognosis (Cai et al., 2018). The gene discussed is AR; the disease is neoplasm.